SCHEMBL3077524

SCHEMBL3077524

CCOC(=O)c1c(Cn2nc(C)c(-c3ccc(C#N)cc3)c2C)cnn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
ELANE P08246 2/20 0.39
AR P10275 2/20 0.39
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
ALOX15 P16050 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
APAF1 O14727 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081302 0.87 AR (0.37) ALDH1A1KDM4EHPGDARMAPT
SCHEMBL3081244 0.75 ALDH1A1 (0.42) ALDH1A1KDM4EGAAHPGDELANE
SCHEMBL4296452 0.73 HPGD (0.44) ALDH1A1KDM4EGAAHPGDMAPT
SCHEMBL3069269 0.70 ALDH1A1 (0.52) ALDH1A1KDM4EGAAHPGDELANE
SCHEMBL3073295 0.69 AR (0.41) ARMAPT
SCHEMBL3070064 0.69 AR (0.65) ALDH1A1KDM4EGAAARMAPT
SCHEMBL3080596 0.69 AR (0.53) ALDH1A1GAAARMAPTKMT2A
SCHEMBL4310894 0.67 AR (0.48) AR
SCHEMBL3075829 0.67 AR (0.44) GAAARKMT2AMEN1
SCHEMBL3085330 0.66 AR (0.50) GAAARTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 ALDH1A1 809/4885KDM4E 1414/4885GAA 4868/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 ALDH1A1 816/4885KDM4E 1440/4885GAA 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.